Difference between revisions of "Ceritinib (Zykadia)"
| Line 15: | Line 15: | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
| − | *4/29/2014: [https://web.archive.org/web/20170213201352/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm395299.htm | + | *4/29/2014: [https://web.archive.org/web/20170213201352/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm395299.htm Accelerated approval] for the treatment of patients with [[Biomarkers#ALK|anaplastic lymphoma kinase (ALK)]]-[[Biomarkers#Rearrangement|positive]] metastatic [[Non-small_cell_lung_cancer|non-small cell lung cancer (NSCLC)]] who have progressed on or are intolerant to [[Crizotinib (Xalkori) | crizotinib]]. |
| − | *5/26/2017: [https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm560873.htm Granted regular FDA approval] for patients with metastatic [[Non-small_cell_lung_cancer | + | *5/26/2017: [https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm560873.htm Granted regular FDA approval] for patients with metastatic [[Non-small_cell_lung_cancer|non-small cell lung cancer (NSCLC)]] whose tumors are [[Biomarkers#ALK|anaplastic lymphoma kinase (ALK)]]-[[Biomarkers#Rearrangement|positive]] as detected by an FDA-approved test. |
==Also known as== | ==Also known as== | ||
Revision as of 05:34, 10 January 2020
General information
Class/mechanism: Tyrosine kinase inhibitor; inhibits anaplastic lymphoma kinase (ALK). Ceritinib prevents growth of ALK-rearranged cancer cells by inhibiting autophosphorylation of ALK and subsequent ALK-mediated phosphorylation of the downstream signaling protein STAT3. In vitro, ceritinib is 20 times as potent against ALK as compared to Crizotinib (Xalkori) and inhibits growth of cells expressing EML4-ALK and NPM-ALK fusion proteins. Ceritinib has been observed in EML4-ALK-rearranged non-small cell lung cancer xenograft models to have activity against crizotinib-sensitive and crizotinib-resistant tumors. Ceritinib also inhibits the insulin-like growth factor 1 receptor (IGF-1R), insulin receptor (InsR), and ROS1. It does not inhibit MET.[1][2][3][4]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
- Ceritinib (Zykadia) package insert[1]
- Ceritinib (Zykadia) patient drug information (Chemocare)[5]
- Ceritinib (Zykadia) patient drug information (UpToDate)[6]
History of changes in FDA indication
- 4/29/2014: Accelerated approval for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib.
- 5/26/2017: Granted regular FDA approval for patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test.
Also known as
- Code name: LDK378
- Brand name: Zykadia
References
- ↑ 1.0 1.1 1.2 Ceritinib (Zykadia) package insert
- ↑ Ceritinib (Zykadia) package insert (locally hosted backup)
- ↑ Zykadia manufacturer's website
- ↑ Shaw AT, Kim DW, Mehra R, Tan DS, Felip E, Chow LQ, Camidge DR, Vansteenkiste J, Sharma S, De Pas T, Riely GJ, Solomon BJ, Wolf J, Thomas M, Schuler M, Liu G, Santoro A, Lau YY, Goldwasser M, Boral AL, Engelman JA. Ceritinib in ALK-rearranged non-small-cell lung cancer. N Engl J Med. 2014 Mar 27;370(13):1189-97. link to original article PubMed
- ↑ Ceritinib (Zykadia) patient drug information (Chemocare)
- ↑ Ceritinib (Zykadia) patient drug information (UpToDate)